________________________________________________________

________________________________________________________

The story of cancer therapy has a dividing line.

Therapies once were blunt instruments—knives and poisons. Cancers would be taken out by surgery, radiation and chemotherapy, only to return months or years later.

But about two decades ago, scientists discovered immunotherapy and precision medicines. They harnessed the immune system to chase down malignant cells. Some cancers were cured, others became diseases to be managed.

Recognizing that oncology is poised for additional leaps, Cancer Focus Fund selects first-in-kind treatments that are moving down new biological pathways to take out stubborn cancers. Drugs in our portfolio block multiple immune checkpoints, or target overexpressed proteins on malignancies, use radiotherapies or strike cancer cells just when they begin to repair their own DNA.

If we are successful, cancer will no longer have the final word.

  • Nectin Therapeutics develops a series of novel immunotherapeutic biological drugs, targeting receptors from the nectin protein family across various solid and hematological cancers. [More]

  • Eisbach Bio is focused on precision oncology. Based in Germany, the firm develops drugs that aim to disrupt tumor growth, going after genetic vulnerabilities within cancer cells. Eisbach pioneers first-in-class therapies with fewer side effects. [More]

  • Based in the Netherlands, ISA is developing fully synthetic immune therapies against cancer and persistent virus infections. The company has built a proprietary platform based on its synthetic long peptide technology. [More]

  • KAHR is leveraging proprietary technology to unmask cancer and simultaneously recruiting a targeted immune response. [More]

  • Mereo BioPharma develops innovative therapeutics for rare diseases. The firm trades on NASDAQ under the stock symbol MREO. [More]

  • Based in Houston, Texas, March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers. [More]

  • ImmunoGenesis is a clinical-stage biopharmaceutical company re-envisioning the treatment of cold tumors, which account for more than half of all cancers. [More]

  • Starget Pharma is an early-stage clinical company developing a new class of Smart Targeted Radioligands for precision oncology of hard-to-heal cancers. [More]